ISSN 1662-4009 (online)

ey0017.14-9 | (1) | ESPEYB17

14.9. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

SA Harrison , MR Bashir , CD Guy , R Zhou , CA Moylan , JP Frias , N Alkhouri , MB Bansal , S Baum , BA Neuschwander-Tetri , R Taub , SE Moussa

To read the full abstract: Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6.Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist. This 36-week long randomised, placebo-controlled trial in 348 US adults with biopsy confirmed non-alcoholic steatohepatitis (fibrosis stages 1–3) shows that Resmetirom...

ey0015.15-7 | New treatments | ESPEYB15

15.7 NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

SA Harrison , ME Rinella , MF Abdelmalek , JF Trotter , AH Paredes , HL Arnold , M Kugelmas , MR Bashir , MJ Jaros , L Ling , SJ Rossi , AM DePaoli , R Loomba

To read the full abstract: Lancet 2018;391:1174-1185Non-alcoholic fatty liver disease is highly prevalent in overweight and obese children and adults. It progresses to steatohepatitis (with raised liver transaminase levels) and fibrosis, and eventually to cirrhosis. Detecting this, excluding other causes of liver disease, and monitoring its progress t...